Delaying Denosumab Dose Boosts Risk for Vertebral Fractures Delaying Denosumab Dose Boosts Risk for Vertebral Fractures
Patients who delayed the recommended 6-month dose by more than 16 weeks were nearly four times more likely to suffer vertebral fractures, according to a new the study.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - July 28, 2020 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

Vertebral Fractures Up With Long-Term Delay of Denosumab
TUESDAY, July 28, 2020 -- Compared with on-time dosing, delay of denosumab by more than 16 weeks is associated with an increased risk for vertebral fractures, according to a study published online July 28 in the Annals of Internal Medicine. Houchen... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2020 Category: Pharmaceuticals Source Type: news

Zoledronate After Denosumab Does Not Fully Prevent Bone Loss Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - June 18, 2020 Category: Orthopaedics Tags: Family Medicine/Primary Care News Source Type: news

Denosumab for the prevention of falls in older people: we need more evidence - Wu XD, Huang W, Qiu GX.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - June 9, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Prolia (denosumab)
Title: Prolia (denosumab)Category: MedicationsCreated: 4/17/2020 12:00:00 AMLast Editorial Review: 4/17/2020 12:00:00 AM (Source: MedicineNet Senior Health General)
Source: MedicineNet Senior Health General - April 17, 2020 Category: Geriatrics Source Type: news

BMD After Transitioning From Denosumab to Alendronate BMD After Transitioning From Denosumab to Alendronate
How might a switch from denosumab to alendronate impact BMD parameters among postmenopausal women?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

A pooled analysis of fall incidence from placebo-controlled trials of denosumab - Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M, Chines A, Huang S, Cummings SR.
Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo-controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower incide... (Source: SafetyLit)
Source: SafetyLit - February 1, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Denosumab in Patients With Fibrous Dysplasia Denosumab in Patients With Fibrous Dysplasia
Denosumab may provide a safe and effective treatment alternative for fibrous dysplasia patients who do not adequately respond to bisphosphonate therapy.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 24, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Denosumab Tied to Infection Risk Denosumab Tied to Infection Risk
The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared to placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

' Bad News': Adjuvant Denosumab Disappoints in Early Breast Cancer'Bad News': Adjuvant Denosumab Disappoints in Early Breast Cancer
Adjuvant denosumab failed to show any clinical benefit on bone metastasis or disease recurrence in high-risk, early breast cancer in the phase 3 D-CARE trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Havertown Doctor Pleads Guilty to Unlawfully Importing Foreign, Injectable Drugs and Unlawfully Distributing Oxycodone
Thomas Whalen, Havertown PA, Guilty plea, importation, heath care fraud, oxycodone, D.O., controlled substance, Whalen Rheumatology Group, Exton PA, Wilmington DE, Unapproved, Injection, Infusion, Remicade Synvisc, Synvisc-One, Orencia, Prolia/Xgeva, Boniva (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - December 19, 2019 Category: Medical Law Authors: DOJ Source Type: news

Denosumab Increasingly Used in Myeloma Despite High Cost Denosumab Increasingly Used in Myeloma Despite High Cost
Denosumab has captured 40% of the market share in just over a year despite a lack of superiority with zoledronic acid and a much higher price tag.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Big Gains With Denosumab in Osteoporosis a Risk for Later Decline Big Gains With Denosumab in Osteoporosis a Risk for Later Decline
Post-hoc analysis of DAPS study shows those who had greatest gains in BMD on denosumab were more likely to have losses when taking a bisphosphonate thereafter.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 23, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier
The combination of high-dose teriparatide with denosumab could represent an ideal intervention for postmenopausal women with osteoporosis at very high risk of fracture; cost is a concern, however.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 29, 2019 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Congratulations to our 2020 Endocrine Nurse Award winner
Join us in congratulating our 2020Endocrine Nurse Award winner, Sherwin Criseno, Advanced Nurse Practitioner/Lead Nurse Endocrinology at University Hospitals Birmingham NHS Trust.He was selected for his project entitled ‘An integrated approach to caring for older people: UHB-Lloyds Pharmacy Prolina Injection Project2 and will present on this atEndocrine Nurse Update 2020.TheSociety Endocrine Nurse Award aims to recognise individuals who have demonstrated innovative and successful nurse-led initiatives in the endocrine field that have advanced best practice in research, education or patient care. This pro...
Source: Society for Endocrinology - August 2, 2019 Category: Endocrinology Source Type: news

Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates
For osteoporosis patients on bisphosphonates for more than a year, switching to teriparatide rather than denosumab should be done with caution, especially for those at high risk of hip fracture, although denosumab has risks of its own, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Denosumab vs Bisphosphonates in Patients With Osteoporosis Denosumab vs Bisphosphonates in Patients With Osteoporosis
Denosumab and bisphosphonates are commonly used medications for the treatment of osteoporosis. Which is more effective?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Fracture-Risk Reduction Continues With Long-Term Denosumab Fracture-Risk Reduction Continues With Long-Term Denosumab
Extended treatment with denosumab is associated with continued reduction in nonvertebral fracture (NVF) rates, according to new findings.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - June 13, 2019 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs Time to Update & quot;Routine, Repeated & quot; Use of Bone Metastasis Drugs
Dr Mark Kris discusses the use of zoledronic acid and denosumab for preventing problems brought on by bone metastases.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Amgen Reports First Quarter 2019 Financial Results
THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include: Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018. Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib) showed double-digit growth. GAAP earnings per share (EPS) decreased 2 percent to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding. ...
Source: Amgen News Release - April 30, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Osteoporotic Fracture Rates Similar With Denosumab, Alendronate in Real World Osteoporotic Fracture Rates Similar With Denosumab, Alendronate in Real World
Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 26, 2019 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

Denosumab cost effective in patients with multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2019 Category: Drugs & Pharmacology Source Type: news

New Guidelines Address Osteoporosis Treatment Postmenopause New Guidelines Address Osteoporosis Treatment Postmenopause
The Endocrine Society's new guidelines advise bisphosphonates and denosumab as first line for lower-risk women and anabolic treatments as first line for those at very high fracture risk.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 26, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

ONJ Rare After Dental Work While on Denosumab for Osteoporosis ONJ Rare After Dental Work While on Denosumab for Osteoporosis
The 7-year FREEDOM Extension trial found that postmenopausal women receiving denosumab for osteoporosis had a low risk of oral necrosis of the jaw (ONJ), even after major dental work.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Denosumab Plus AI Therapy Can Improve Outcomes in HR+ Breast Cancer
The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Adjuvant Denosumab Improved DFS in HR+ Breast Ca
(MedPage Today) -- Results establish denosumab as alternative to bisphosphonates (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 24, 2019 Category: Endocrinology Source Type: news

Study Quantifies Dental, Jaw Risks With Denosumab
(MedPage Today) -- 10-year data suggest oral issues common (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 14, 2019 Category: Endocrinology Source Type: news

Rates of Osteonecrosis of the Jaw Low for Denosumab-Treated Women
THURSDAY, Feb. 14, 2019 -- For denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2019 Category: Pharmaceuticals Source Type: news

Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include: For the fourth quarter, total revenues increased 7 percent to $6.2 billion. Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product s...
Source: Amgen News Release - January 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Denosumab Promising for TDT - Induced Osteoporosis Treatment
Higher percentage increase of L1 to L4 and wrist bone mineral density with DMN, reduction in pain (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 13, 2018 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Gynecology, Internal Medicine, Oncology, Orthopedics, Pharmacy, Journal, Source Type: news

Denosumab Promising for TDT-Induced Osteoporosis Treatment
TUESDAY, Nov. 13, 2018 -- Denosumab (DNM), a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), may be beneficial for managing transfusion-dependent thalassemia (TDT)-induced osteoporosis,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news

Denosumab not cost effective for treatment of bone metastases
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Reports Third Quarter 2018 Financial Results
THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion. Product sales grew 1 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 4 percent to $2.86 driven by higher total revenues, a lower tax rate and lower weighted-average shares out...
Source: Amgen News Release - October 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Can Rare Rebound Fractures After Denosumab Therapy Be Avoided? Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?
Two studies suggest rare rebound vertebral fractures after stopping denosumab may be averted by giving a potent bisphosphonate and not continuing aromatase inhibitors beyond 6 months of stopping.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ONJ With Bone-Modifying Agents in Breast Cancer Patients ONJ With Bone-Modifying Agents in Breast Cancer Patients
Osteonecrosis of the jaw was reported in metastatic breast cancer patients treated with bone-modifying agents; the incidence was higher with denosumab compared with bisphosphonates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion. Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth. GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares o...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer
The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) h... Biopharmaceuticals, Regulatory Amgen, Prolia , denosumab, osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 8, 2018 Category: Pharmaceuticals Source Type: news

European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid tre...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Denosumab subsidised by PHARMAC for osteoporosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

New Denosumab Indication; Seafood & Fertility; World Thyroid Day
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - May 25, 2018 Category: Pediatrics Source Type: news

FDA Approves Denosumab for Steroid-Induced Osteoporosis FDA Approves Denosumab for Steroid-Induced Osteoporosis
The US FDA has approved denosumab (Prolia, Amgen) for treatment of glucocorticoid-induced osteoporosis. European regulators recently green-lighted the same indication.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Prolia ® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Fifth Indication for Prolia for Men and Women at High Risk of Fracture Receiving Systemic Glucocorticoid Therapy THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data...
Source: Amgen News Release - May 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 21, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture THOUSAND OAKS, Calif., April 27, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal... Biopharmaceuticals, Regulatory Amgen, Prolia, denosumab, Glucocorticoid-Induced, Osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2018 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia ® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture THOUSAND OAKS, Calif., April 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. "Today's positive opinion by the CHMP is an important step for Prolia in help...
Source: Amgen News Release - April 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

UAB-led study shows drug effectiveness in reducing glucocorticoid-induced bone loss
(University of Alabama at Birmingham) About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce glucocorticoid-induced bone loss, causing an estimated yearly bone fracture rate of 5 percent. An alternative treatment option to the standard treatment now appears promising, according to an international study. Researchers compared the monoclonal antibody denosumab against a standard bisphosphonate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2018 Category: International Medicine & Public Health Source Type: news

Amgen Reports First Quarter 2018 Financial Results
THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent versus the first quarter of 2017 to $5.6 billion. Product sales grew 3 percent globally. All new and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 16 percent to $3.25 driven by higher product sales, a lower tax rate and lower weighted-average shares...
Source: Amgen News Release - April 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Benefits, Drawbacks to Denosumab Tx in ESRD
(MedPage Today) -- High rates of treatment-related hypocalcemia (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 12, 2018 Category: Endocrinology Source Type: news

Steroid-Induced Bone Loss Better Treated With Denosumab? Steroid-Induced Bone Loss Better Treated With Denosumab?
Denosumab found to be superior to risedronate in the treatment of steroid-induced osteoporosis at 12 months, at least in terms of BMD, among patients starting steroid therapy or those who remained on it.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news